TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17615828
Drug: Active intervention
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active intervention PCG (children received a series of interventions including gift bags with a trainer cup, fluoride toothpaste (1450 ppm F), toothbrush, and parental advice on oral care)
Study: 25016482
Drug: Atorvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (10 mg daily)
Study: 11718678
Drug: Mulberry therapy
Normalized name: MULBERRY
DrugBank: Broussonetia papyrifera pollen (DB10736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mulberry therapy
Study: 1628772
Drug: Glibenclamide treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide treatment
Study: 1672049
Drug: esmolol 1
Normalized name: esmolol 10 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: esmolol 1 mg/kg
Study: 22463973
Drug: IV pantoprazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV pantoprazole, antacid, and antispasmodic
Study: 22463973
Drug: Placebo, antacid,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, antacid, and antispasmodic (conventional group)
Study: 18365224
Drug: 1 x
Normalized name: Black Cohosh 1 X Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 6 mL hylan G-F 20
Study: 18365224
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 2 mL hylan G-F 20
Study: 18365224
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 4 mL hylan G-F 20 (2 weeks apart)
Study: 17229535
Drug: Bifidobacter lactis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacter lactis supplemented preterm formula (2 x 10(7) cfu/g of dry milk)
Study: 2544742
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) - 2,500 units 2 hours before surgery, then 5,000 units subcutaneously every morning for 9 days
Study: 2544742
Drug: Conventional low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Conventional low-dose heparin - 5,000 units every 8 hours
Study: 31642731
Drug: ACT-541468 25
Normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACT-541468 25 mg (repeated evening administration)
Study: 24867846
Drug: Frovatriptan 2.5
Normalized name: frovatriptan 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frovatriptan 2.5 mg + dexketoprofen 25 mg (FroDex25)
Study: 24867846
Drug: Frovatriptan 2.5
Normalized name: frovatriptan 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frovatriptan 2.5 mg + dexketoprofen 37.5 mg (FroDex37.5)
Study: 19915475
Drug: I-gel, pLMA,
Approvals — FDA: no, EMA: no, PMDA: no
Description: I-gel, pLMA, cLMA
Study: 16059992
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (1000 mg/12 h infusion followed by 1200 mg/24 h orally) and Vitamin E (600 mg/24 h)
Study: 1387607
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose adrenaline infusion
Study: 6469443
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg buflomedil
Study: 6469443
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg buflomedil
Study: 7034592
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg buflomedil
Study: 6927816
Drug: 2000 mg
Normalized name: bran 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 mg piracetam
Study: 21179732
Drug: Intravenous dripping
Normalized name: DRIP COLLECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dripping of immunoglobulin for 3 months (Control)
Study: 12016811
Drug: IVIgG (100‐300
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIgG (100‐300 mg.kg‐1.d‐1) for 2‐3 days
Study: 10907942
Drug: 30 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/day tamoxifen
Study: 23411616
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy without candesartan (n=543)
Study: 20094823
Drug: Corticosteroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid therapy in asthmatic patients
Study: 19232940
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of ephedrine per 20 mL of propofol (Group E15)
Study: 19232940
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of ephedrine per 20 mL of propofol (Group E30)
Study: 19232940
Drug: 1% lidocaine
Normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% lidocaine per 20 mL of 1% propofol (Group L)
Study: 15385385
Drug: endotracheal lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: endotracheal lidocaine 160 mg
Study: 11427213
Drug: avasimibe 250
Normalized name: Avasimibe
DrugBank: Avasimibe (DB06442)
Approvals — FDA: no, EMA: no, PMDA: no
Description: avasimibe 250 mg
Study: 11427213
Drug: avasimibe 500
Normalized name: Avasimibe
DrugBank: Avasimibe (DB06442)
Approvals — FDA: no, EMA: no, PMDA: no
Description: avasimibe 500 mg
Study: 9441080
Drug: Chemotherapy (SCC)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (SCC) regimen
Study: 2401176
Drug: Surgery plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery plus chemotherapy
Study: 2008945
Drug: Awake extubation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Awake extubation (either agent)
Study: 7829769
Drug: Intravenous L-tryptophan
Normalized name: L-TRYPTOPHAN
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous L-tryptophan (TRP)
Study: 21366472
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of furosemide
Study: 31371212
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy (CBT) plus placebo
Study: 31371212
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy (CBT) plus fluoxetine (20 mg daily)
Study: 28346003
Drug: 1% diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% diclofenac sodium cream applied topically every 12 hours for 7 days
Study: 28346003
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream applied topically every 12 hours for 7 days
Study: 15367427
Drug: Transfusion with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfusion with a target dose of 1 x 10(11)/10 kg (arm B)
Study: 6546371
Drug: Pirenzepine 25
Normalized name: pirenzepine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine 25 mg
Study: 30036739
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bevacizumab, oxaliplatin and fluoropyrimidine
Study: 22187070
Drug: Regular colonoscopy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular colonoscopy (CC)
Study: 18552687
Drug: Protocolized Sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocolized Sedation + Daily Interruption (PS + DI)
Study: 12218525
Drug: Low-dose dexmedetomidine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dexmedetomidine (target plasma concentration 0.3 ng/ml)
Study: 12218525
Drug: Dexmedetomidine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (both doses) during shivering
Study: 8725976
Drug: Cholesterol Treatment
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol Treatment Program (CTP)
Study: 1355923
Drug: Yohimbine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (20 mg)
Study: 31099992
Drug: RD3 (dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RD3 (dexmedetomidine at an initial dose of 0.5 μg/kg for 10 min adjusted to 0.6 μg kg−1 hr−1 throughout EIT)
Study: 25193490
Drug: Video administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video administered at one month (early intervention)
Study: 25193490
Drug: Video administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video administered at seven months (late intervention)
Study: 22927525
Drug: Cetuximab 250
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab 250 mg/m(2)
Study: 22927525
Drug: Cetuximab 250
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab 250 mg/m(2) with paclitaxel 80 mg/m(2)
Study: 20496732
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Fluoxetine
Study: 17258855
Drug: Alfuzosin 10
Normalized name: Alfuzosin 10mg Oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin 10 mg OD
Study: 12218722
Drug: E/NETA 0.25-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: E/NETA 0.25-mg group
Study: 12218722
Drug: E/NETA 0.5-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: E/NETA 0.5-mg group
Study: 7893027
Drug: Lidocaine with
Normalized name: Lidocaine with Tegaderm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine with epinephrine (0.2 mg)
Study: 22669692
Drug: Fipronil spot-on
Normalized name: fipronil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fipronil spot-on formulation (26.8 mg a.i./kg)
Study: 22669692
Drug: Fipronil spray
Normalized name: fipronil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fipronil spray formulation
Study: 15730535
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) 200 mg
Study: 8542895
Drug: Talcid (hydrotalcite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talcid (hydrotalcite 1 g)
Study: 8542895
Drug: Maalox (Mg‐Al‐hydroxide)
Normalized name: aluminum hydroxide / magnesium hydroxide / simethicone Oral Suspension [Maalox Plus]
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maalox (Mg‐Al‐hydroxide)
Study: 1822599
Drug: Continuous spinal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous spinal anesthesia (CSA) with 1.9 ml bupivacaine HCl 0.5%
Study: 1822599
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural anesthesia (CEA) with 12.6 ml bupivacaine HCl 0.5%
Study: 6787417
Drug: Timolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol (10 mg twice daily)
Study: 23864516
Drug: Delayed-treatment contact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-treatment contact group
Study: 19878298
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment with calcipotriol
Study: 18417354
Drug: Sun bed
Normalized name: CLOZAPINE (SUN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sun bed exposure (0.5 to 1 MED, twice per week for 4 weeks)
Study: 18417354
Drug: Daily supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplement of 200 IU vitamin D (cod liver oil capsules)
Study: 12687466
Drug: Daily calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily calcitriol (10 ng/kg per day)
Study: 12687466
Drug: Intermittent calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent calcitriol (35 ng/kg twice a week)
Study: 10227453
Drug: Oxymetholone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymetholone (2 mg/m2/d)
Study: 9172009
Drug: Buprenorphine (0.2‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (0.2‐mg sublingual tablet every 6‐8 h)
Study: 31166287
Drug: BAK-preserved latanoprost-timolol
Normalized name: latanoprost / timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAK-preserved latanoprost-timolol fixed combination
Study: 24313619
Drug: Porcine placental
Normalized name: Secretin porcine
DrugBank: Secretin porcine (DB09527)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Porcine placental extract (PPE), 6 capsules per day
Study: 22967105
Drug: telbivudine 600
Normalized name: telbivudine 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: telbivudine 600 mg
Study: 22967105
Drug: lamivudine 100
Normalized name: lamivudine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lamivudine 100 mg
Study: 19005477
Drug: Device-guided breathing
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Device-guided breathing (RESPeRATE), 15 min daily for 8 weeks
Study: 19005477
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (regular treatment)
Study: 16444853
Drug: Warfarin group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin group
Study: 26026705
Drug: 24 intranasal
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 intranasal units (IU) oxytocin
Study: 24145941
Drug: Evidence based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence based medicine (EBM) workshop
Study: 17485550
Drug: Real‐time quantitative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real‐time quantitative polymerase chain reaction analysis of antigen receptor gene rearrangements for detection of minimal residual disease (MRD)
Study: 11175930
Drug: Metered Dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered Dose Inhaler (MDI) with spacer
Study: 26332915
Drug: Immediate PBM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate PBM therapy (2 min treatment using a 4 W laser beam, 171 J delivered)
Study: 21724005
Drug: Regional intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regional intravenous anesthesia with lidocaine
Study: 21724005
Drug: Regional intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regional intravenous anesthesia with lidocaine and clonidine
Study: 16476941
Drug: SIB-1508Y (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIB-1508Y (10 mg daily)
Study: 11908373
Drug: Electric toothbrush
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electric toothbrush (Braun Oral‐B Plaque Remover)
Study: 8295604
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of DHE 2 mg and paracetamol 1000 mg
Study: 15054681
Drug: Topical metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical metronidazole (10 percent)
Study: 17184625
Drug: Self-management of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management of oral anticoagulation
Study: 1390306
Drug: Low-dose continuous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose continuous heparin
Study: 23602777
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg daily
Study: 17407626
Drug: escitalopram 10
Normalized name: escitalopram 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: escitalopram 10 mg/day
Study: 31105027
Drug: escitalopram 20
Normalized name: escitalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: escitalopram 20 mg/day
Study: 10559616
Drug: Tamsulosin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.4 mg modified release formulation once daily)
Study: 1825323
Drug: etodolac 200
Normalized name: etodolac 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: etodolac 200 mg b.i.d.
Study: 8566633
Drug: naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen 500 mg b.i.d.
Study: 6836825
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of gentamicin two hours preoperatively
Study: 6836825
Drug: Three schedules
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three schedules of gentamicin administration
Study: 30316534
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (50,000 U vitamin D3 pearl weekly for 8 weeks)
Study: 30016983
Drug: Xiaozhen formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiaozhen formula and basic treatment
Study: 30335070
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic treatment only
Study: 21375022
Drug: Routine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine plus mental-regulating acupoints treatment group
Study: 21375022
Drug: Treatment sessions
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment sessions
Study: 17634487
Drug: Long-term androgen-deprivation
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term androgen-deprivation therapy (LTAD) plus radiotherapy (RT)
Study: 16287386
Drug: Mid- and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mid- and late treatment perceptual processing
Study: 11989834
Drug: Prucalopride 1
Normalized name: prucalopride 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prucalopride 1 mg
Study: 11929394
Drug: Prucalopride 1
Normalized name: prucalopride 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prucalopride 1 mg and 2 mg
Study: 7545763
Drug: Daily recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily recombinant human growth hormone (rhGH), 0.15 mg/kg IM
Study: 21413974
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose BoNT‐B (1500 MU)
Study: 21413974
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose BoNT‐B (3000 MU)
Study: 18499270
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate aqueous nasal spray (maintenance therapy)
Study: 12032514
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no growth hormone treatment)
Study: 10232715
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg lidocaine 5% intrathecally (group A)
Study: 10232715
Drug: 0.15 mg
Normalized name: iodine 0.15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg x kg(‐1) meperidine (group B) co-administered with lidocaine
Study: 10232715
Drug: 0.30 mg
Normalized name: Corona Multi-Purpose 0.30 MG/MG Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.30 mg x kg(‐1) meperidine (group C) co-administered with lidocaine
Study: 6676478
Drug: Physostigmine salicylate
Normalized name: PHYSOSTIGMINE SALICYLATE
DrugBank: Physostigmine (DB00981)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine salicylate 0.04 mg kg‐1 BW iv
Study: 22127555
Drug: Alprazolam administration
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprazolam administration
Study: 1608114
Drug: Multidrug chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidrug chemotherapy regimens
Study: 18715415
Drug: Immediate oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate oxytocin administration
Study: 12202899
Drug: Doxorubicin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin and paclitaxel (AT combination)
Study: 7726087
Drug: Delayed imaging
Normalized name: triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed imaging after injection of standard contrast dose
Study: 7726087
Drug: Delayed imaging
Normalized name: triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed imaging after injection of higher contrast dose
Study: 7726087
Drug: Cumulative triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative triple dose (0.3 mmol/kg)
Study: 25774878
Drug: Computer self-administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer self-administration of the CRAFFT screening protocol
Study: 22448928
Drug: Risperidone long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone long-acting injection (RLAI)
Study: 16735934
Drug: raloxifene 60
Normalized name: raloxifene 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: raloxifene 60 mg/day
Study: 1946889
Drug: Beta-adrenergic blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-adrenergic blockers (15 subjects)
Study: 30868491
Drug: Continuous Positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Positive Airway Pressure (CPAP) therapy for 3 months
Study: 14576501
Drug: Imipenem 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem 0.5 g q.i.d. intravenously
Study: 14576501
Drug: Meropenem 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 0.5 g t.i.d. intravenously
Study: 10409530
Drug: atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol 50 mg once daily
Study: 1345218
Drug: co‐amiloride 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: co‐amiloride 25 mg + amiloride 5 mg once daily
Study: 18818847
Drug: In-shower body
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-shower body lotion product form
Study: 7595716
Drug: GM‐CSF treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM‐CSF treatment
Study: 31950267
Drug: Propofol (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (group P) at Ce of 4 μg/ml
Study: 31950267
Drug: Propofol (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (group P) at Ce of 2 or 3 μg/ml
Study: 27346437
Drug: Irbesartan 150-300
Normalized name: irbesartan 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 150-300 mg/day
Study: 26447156
Drug: Choline supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline supplementation (500 mg daily for 9 months)